Dimethyltryptamine levels in blood of schizophrenic patients and control subjects

  title={Dimethyltryptamine levels in blood of schizophrenic patients and control subjects},
  author={Burton M. Angrist and Samuel Gershon and Gregory Sathananthan and Robert W. Walker and Basilio Lopez-Ramos and Lewis R. Mandel and William J. A. Vandenheuvel},
A gas chromatographic-mass spectrometric determination of blood N,N-dimethyltryptamine in normal controls and schizophrenic patients was carried out with a sensitivity limit of 0.05 ng/ml whole blood. Although the results appear to suggest that the mean DMT level was higher in the total patient group, those patients with acute psychosis, female patients and patients with suspiciousness scores on the BPRS of 4 or over, the differences were not statistically significant. 
The Excretion of Dimethyltryptamine in Psychiatric Patients
Recent advances in neurochemistry and in the standardization of psychiatric symptomatology and classification have facilitated the emergence of coherent testable hypotheses, and one of these predicts that the abnormal metabolism of methylated indoleamines may be a factor in the genesis of some of the symptoms of schizophrenia. Expand
Factors affecting the urinary excretion of endogenously formed dimethyltryptamine in normal human subjects
The hallucinogenic substance N′,N′-dimethyltryptamine and its precursor N-methylryptamine were found in 24-h speciments of urine from 19 normal human subjects and the urinary excretion of both compounds was unrelated to age, sex, urinary volume, or creatinine, nor was any consistent diurnal pattern observed. Expand
Endogenous psychoactive tryptamines reconsidered: an anxiolytic role for dimethyltryptamine.
It is proposed that endogenous DMT interacts with the TA receptor to produce a calm and relaxed mental state, which may suppress, rather than promote, symptoms of psychosis, and amphetamine action at the TA receptors may contribute to the calming effects of amphetamine and related drugs, especially at low doses. Expand
Dimethyltryptamine: Possible Endogenous Ligand of the Sigma-1 Receptor?
[1] Manske RHF (1931) A synthesis of the methyltryptamines and some derivatives. Can J Res 5: 592–600 [2] Szára S (1956) Dimethyltryptamin: its metabolism in man; the relation to its psychotic effectExpand
A critical review of reports of endogenous psychedelic N, N-dimethyltryptamines in humans: 1955-2010.
A critical review of 69 published studies reporting the detection or detection and quantitation of these compounds in human body fluids addresses the methods applied and the criteria used in the determination of the presence of DMT, MDMT, and HDMT. Expand
Potentially hallucinogenic 5‐hydroxytryptamine receptor ligands bufotenine and dimethyltryptamine in blood and tissues
A new finding was the detection of large amounts of bufotenine in stools, which may be an indication of its role in intestinal function, and only small amounts of the DMIAs were found in somatic or neural tissues and none in blood. Expand
Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter
High binding-to-uptake ratios support the hypothesis that the tryptamines are transporter substrates, not uptake blockers, at both SERT and VMAT2, and indicate that there are separate substrate and inhibitor binding sites within these transporters. Expand
Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions.
5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) belongs to a group of naturally-occurring psychoactive indolealkylamine drugs. It acts as a nonselective serotonin (5-HT) agonist and causes manyExpand
The natural hallucinogen 5-MeO-DMT, component of Ayahuasca, disrupts cortical function in rats: reversal by antipsychotic drugs.
The observed cortical alterations are related to the psychotomimetic action of 5-MeO-DMT, and the present model may help to understand the neurobiological basis of hallucinations and to identify new targets in antipsychotic drug development. Expand
Effects of Hallucinogens on Neuronal Activity.
The disruption of PFC activity induced by PCP, DOI and 5-MeO-DMT is reversed by classical and atypical antipsychotic drugs, suggesting a possible link between the mechanisms underlying the disruption of perception by multiple classes of hallucinogenic agents and the therapeutic efficacy of antipsychotics. Expand


Gas chromatographic-mass spectrometric isotope dilution determination of N,N-dimethyltryptamine concentrations in normals and psychiatric patients
A gas chromatographic-mass spectrometric determination of the plasma N,N-dimethyltryptamine concentration from normals and psychiatric patients revealed that within the limit of sensitivity of theExpand
Reduced Monoamine Oxidase Activity in Platelets: A Possible Genetic Marker for Vulnerability to Schizophrenia
The data suggest, but do not prove, that reduced platelet monoamine oxidase activity may provide a genetic marker for vulnerability to schizophrenia. Expand
Gas chromatographic-mass spectrometric isotope dilution assay for N,N-dimethyltryptamine in human plasma.
An isotope dilution assay for the determination of N,N-dimethyltryptamine in human plasma has been developed and serves as an internal standard in a gas chromatographic-mass spectrometric analysis of the final isolate. Expand
Action of psychotogenic drugs on single midbrain raphe neurons.
The results indicate that the indole and phenethylamine psychotogens, which have similar effects on behavior, also have an overlapping although not identical effect on single units in the raphe nuclei. Expand
N,N-dimethyltryptamine--a possible relationship to schizophrenia?
Action ofpsychotogenic drugs in single raphe neurons
  • J . Pharmacol . exp . Ther .
  • 1970
Review of rapid urine tests for phenothiazine and related drugs.